PubMed · 1995 · 21 citations · 31 references
MedicineImmunologyOncologyCancer ImmunologyImmunoregulationTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyImmune Cell SignalingT Cell Responses To TumorsTumor Microenvironment ModulationCancer-associated ImmunosuppressionGanglioside CompositionHost Immune ModulationHost-mediated Tissue DestructionImmune-mediated Tissue DestructionImmunosuppressive FunctionTumor Immunosurveillance
Gangliosides are immunosuppressive to many classes of immune cells, and shedding of these glycosphingolipids by tumour cells may regulate immune responses in cancer, and protect tumours from host immune destruction. One mechanism of immunosuppression by gangliosides in vitro involves competition with interleukin-2 receptors (IL-2R) for binding of IL-2. Previous studies on inhibition of IL-2-mediated events by gangliosides have been conducted in the presence of high levels of fetal bovine serum (FBS). However, gangliosides shed by tumours in vivo will encounter immune cells in the low protein microenvironment of the tissue fluid. In order to better mimic physiological conditions, we have examined immunosuppression by gangliosides towards IL-2-dependent HT-2 cells in a low serum-low protein medium. The ability of gangliosides to inhibit IL-2-stimulated DNA synthesis in HT-2 increased dramatically as the serum concentration in the culture medium was decreased; the 50% inhibitory concentration (IC50) value for GM1 was 13 microM under low serum conditions, 14-fold lower than the value obtained in 10% FBS. Further investigation revealed that the mechanism of immunosuppression by gangliosides in low serum-low protein medium involved interference with the IL-2/IL-2R system. Ganglioside-mediated inhibition was dependent on the continued presence of the glycolipids during the first few hours after IL-2 stimulation, and could be reversed by increasing levels of IL-2. Receptor binding experiments demonstrated that gangliosides blocked the interaction of IL-2 with high-affinity IL-2 receptors on HT-2. Taken together, these results support the view that gangliosides will act as much more potent suppressors of IL-2-dependent processes in vivo in the vicinity of a tumour.
31
Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides.
Stephan Ladisch, Baiba K. Gillard, Clifford Wong et al. · PubMed · 1983 · 190 citations
Gangliosides in normal human serum
Hans‐Jürgen SENN, Matthias Orth, Edith Fitzke et al. · European Journal of Biochemistry · 1989 · 161 citations · Full text
Shed tumor gangliosides and progression of human neuroblastoma
L Valentino, Thalia Moss, E Olson et al. · Blood · 1990 · 135 citations · Full text
Shedding of G<sub>D2</sub> ganglioside by human neuroblastoma
Zi‐Liang Wu, Stephan Ladisch, Stephen A. Feig et al. · International Journal of Cancer · 1987 · 134 citations